SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
InterMune (nasdaq)ITMN
An SI Board Since March 2000
Posts SubjectMarks Bans Symbol
508 36 0 ITMN
Emcee:  Secret_Agent_Man Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
508And out from the cracks in the woodwork they rush forth..... Block &Savant-8/26/2014
507 Roche/ITMN Deal Hoists First Trust Biotech ETF to Record High -- MarSavant-8/26/2014
506 Roche to buy InterMune for $8.3 billionBy Jonathan D. RockoffSavant-8/25/2014
505 InterMune Receives FDA Breakthough Therapy Designation For PirfenidoSavant-7/28/2014
504 InterMune beats by $0.04, beats on revs; raises FY14 revs in-line wiSavant-5/13/2014
503I still have a position in ITMN though its not as big as it once was. I think tghmm-11/6/2013
502One Q on ITMN is where will the share price stabilize? Will it be in the low $1Biotech Jim-11/6/2013
501secondary killing ppshdl-11/6/2013
500In the FWIW column, the Baker Bros. Hedge Fund picked up a significant stake in Biotech Jim-12/12/2012
499Very Interesting study of Pirfenidone. I recall a very early pilot study that tghmm-12/1/2012
498Ian Estepan ?@ianestepan $ITMN May IMS data for Germany released:16% mo/mo growtghmm-7/5/2012
497Interesting article on Pirfenidone. Granted its a meta-analysis but should helpghmm-6/3/2012
496The other day Ian Estepan ? @ianestepan tweeted that IMS data showed 2 - 2.3 mighmm-6/1/2012
495Bosentan in IPF results are posted at clinicaltrials.gov. I am impressed with tghmm-6/1/2012
494Title: InterMune to Divest Actimmune® (Interferon Gamma-1b) Date(s): 5/21tnsaf-5/22/2012
493I don't think it's all that surprising that if you immune-suppress old pBiomaven-5/21/2012
492I found the imbalance in acute exacerbation very interesting especially given noghmm-5/21/2012
491One "standard" treatment turns out to be harmful: BACKGROUNDA combinBiomaven-5/20/2012
490Speaking of Fibrogen here is a link to the changes in their Phase 2 study (just ghmm-5/16/2012
489This issue of potential side effects came to mind when I saw the view from PK-PDBiotech Jim-5/16/2012
488Jim, do you think that there will be side effects of the CTGF mAb on chondrogenBiomaven-5/16/2012
487Below is that PR from Fibrogen. I do not disagree with you on this Peter, but I Biotech Jim-5/16/2012
486No doubt a second approved drug for IPF would hurt ITMN stock. I've heard Dghmm-5/16/2012
485But the Fibrogen IPF PR does create some new and substantial long-term risk hereBiomaven-5/15/2012
484In the FWIW column: I like the recent action in the ITMN stock since the latestBiotech Jim-5/7/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News